July 21, 2021 – ZOLL Medical Corporation (Chelmsford, MA), an Asahi Kasei company, announced that it has received FDA 510(k) clearance to release the TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator.
TBI Dashboard provides clinical decision support for managing patients with TBI (traumatic brain injury) and was previously available on Propaq devices in international markets.
With the FDA clearance announced today, ZOLL can now bring this capability to the U.S. market.
TBI Dashboard displays numeric and graphical trend data on what the EPIC study refers to as the “three H-bombs”: hypotension, hypoxia, and hyperventilation. Providing continuously updated vital-signs data at a glance allows medical personnel to make treatment decisions before a patient’s status becomes critical, as recommended by the TCCC guidelines and demonstrated by the EPIC study.
In addition to monitoring key vital signs, TBI Dashboard also includes a breath-by-breath countdown timer to help care providers maintain proper ventilation rates and prevent hyperventilation.
From the point of injury throughout the continuum of en-route care, ZOLL’s Propaq M and Propaq MD monitor/defibrillators, now with TBI Dashboard capabilities, support rapid treatment and effective management of TBI patients. TBI Dashboard is also available and approved for use on ZOLL’s X Series Advanced monitor/defibrillator.